chrX-101349551-A-C
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000061.3(BTK):c.*334T>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0139 in 229,791 control chromosomes in the GnomAD database, including 113 homozygotes. There are 668 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.025 ( 100 hom., 605 hem., cov: 22)
Exomes 𝑓: 0.0039 ( 13 hom. 63 hem. )
Consequence
BTK
NM_000061.3 3_prime_UTR
NM_000061.3 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.347
Genes affected
BTK (HGNC:1133): (Bruton tyrosine kinase) The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant X-101349551-A-C is Benign according to our data. Variant chrX-101349551-A-C is described in ClinVar as [Benign]. Clinvar id is 367692.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.0842 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BTK | NM_000061.3 | c.*334T>G | 3_prime_UTR_variant | 19/19 | ENST00000308731.8 | NP_000052.1 | ||
BTK | NM_001287344.2 | c.*334T>G | 3_prime_UTR_variant | 19/19 | NP_001274273.1 | |||
BTK | NM_001287345.2 | c.*334T>G | 3_prime_UTR_variant | 17/17 | NP_001274274.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BTK | ENST00000308731.8 | c.*334T>G | 3_prime_UTR_variant | 19/19 | 1 | NM_000061.3 | ENSP00000308176 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0251 AC: 2717AN: 108243Hom.: 99 Cov.: 22 AF XY: 0.0193 AC XY: 602AN XY: 31173
GnomAD3 genomes
AF:
AC:
2717
AN:
108243
Hom.:
Cov.:
22
AF XY:
AC XY:
602
AN XY:
31173
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00385 AC: 468AN: 121500Hom.: 13 Cov.: 0 AF XY: 0.00213 AC XY: 63AN XY: 29584
GnomAD4 exome
AF:
AC:
468
AN:
121500
Hom.:
Cov.:
0
AF XY:
AC XY:
63
AN XY:
29584
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0252 AC: 2724AN: 108291Hom.: 100 Cov.: 22 AF XY: 0.0194 AC XY: 605AN XY: 31231
GnomAD4 genome
AF:
AC:
2724
AN:
108291
Hom.:
Cov.:
22
AF XY:
AC XY:
605
AN XY:
31231
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
X-linked agammaglobulinemia with growth hormone deficiency Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
X-linked agammaglobulinemia Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at